| Application no. and date | 02772653.8 (espacenet) (Federated) (European Patent Register), 20020905 | | Patent/reg. no. and date | DK/EP 1443933, 20091209 | | Publication date | 20040811 | | Priority no. and date | US 316967 P, 20010905 | | EP pub. no. and date |
EP 1443933 20040811 | | Effective date | | | Applicant/owner | Teva Pharmaceuticals International GmbH, Schlüsselstrasse 12
8645 Jona, CH | | Applicant ref. no. | P46396DK01 | | Inventor | ROBIN, Jean-Pierre, 72, avenue Olivier Messiaen
F-72000 Le Mans, FR,
MAISONNEUVE, Hervé, 22, rue Goya
F-85000 La Roche Sur Yon, FR,
MAHON, François-Xavier, 6, rue Condillac
F-33000 Bordeaux, FR,
BLANCHARD, Julie, 72 avenue Olivier Messiaen
F-72000 Le Mans, FR,
MALOISEL, Frederick,c/o Hôpital de Hautepierre, Avenue Molière
F-67100 Strasbourg, FR | | Representative | Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, DK | | Opponent | | | IPC Class | A61K 31/55 (2006.01) | | Title | Behandling af kronisk myeloid leukæmi, resistent eller intolerant over for sti571, der involverer homoharringtonin alene eller kombineret med andre midler | | Int. application no. | IB2002003992 | | Int. publication no. | WO2003020252 | | Related patent (certificate) | | | Status | Bortfaldet | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
